Company news

AstraZeneca PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

EMA approves AZ's Imfinzi for Stage III NSCLC

September 24, 2018

Farxiga gets positive result in DECLARE-TIMI 58

September 24, 2018

FDA approves AZ's Lumoxiti in hairy cell leukaemia

September 14, 2018

Tezepelumab FDA Breakthrough Therapy Designation

September 7, 2018

AstraZeneca Update on Anifrolumab in SLE

August 31, 2018

EC approves Bydureon BCise device for T2 diabetes

August 30, 2018

AstraZeneca PIIIb trial update for Bevespi in COPD

August 23, 2018

AZ's Tagrisso approved in Japan for 1st-line NSCLC

August 21, 2018

EMA grants OD for selumetinib in NF1

August 3, 2018

CHMP recommends Imfinzi for Stage III nsclc

July 27, 2018

AZN: H1 2018 Results

July 26, 2018

Atacand to be divested to Cheplapharm in Europe

July 24, 2018

Lynparza approved in Japan for BRCAm breast cancer

July 2, 2018

Imfinzi approved in Japan for Stage III nsclc

July 2, 2018

Bydureon receives positive CHMP opinion for BCise

June 29, 2018

AZ and Luye Pharma complete agreement for Seroquel

June 28, 2018

Lynparza: significant PFS 1st-line ovarian cancer

June 27, 2018

Update: lanabecestat Phase III Alzheimer's trials

June 12, 2018

EU approves Tagrisso for 1st-line NSCLC

June 8, 2018

Update on TERRANOVA PIII trial for Fasenra in COPD

May 30, 2018

AZ's Imfinzi: significant OS in Stage III nsclc

May 25, 2018

US FDA approves Lokelma for adult hyperkalaemia

May 21, 2018

AZ regulatory submission in Japan for Forxiga

May 21, 2018

AZN: Q1 2018 Results

May 18, 2018

AstraZeneca update on Fasenra PIII trial in COPD

May 11, 2018

EMA approves Lynparza: maintenance ovarian cancer

May 8, 2018

AZ and Luye Pharma enter agreement for Seroquel

May 8, 2018

AZ: positive CHMP for Tagrisso first-line nsclc

April 27, 2018

AstraZeneca: high level results of the ARCTIC trial

April 24, 2018

FDA approves Tagrisso for 1st-line use in NSCLC

April 19, 2018

FDA to review moxetumomab for Hairy cell leukaemia

April 3, 2018

Az and MSD submit Lynparza for breast cancer in eu

April 3, 2018

Lokelma approved in the EU

March 22, 2018

AstraZeneca updates MYSTIC trial timeline

March 12, 2018

Lynparza CHMP for ovarian cancer maintainance

February 23, 2018

AstraZeneca's IMFINZI approved for Stage III nsclc

February 19, 2018

Selumetinib in NF1 gets FDA orphan drug status

February 15, 2018

AZN: Full-Year 2017 Results

February 2, 2018

AZ Reports Phase III Results for PT010 in COPD

January 26, 2018

Lynparza approved in Japan for ovarian cancer

January 19, 2018

AstraZeneca's Fasenra receives approval in Japan

January 19, 2018

FDA approves Lynparza for metastatic breast cancer

January 12, 2018

AstraZeneca's Fasenra approved in the EU

January 10, 2018

FDA accepts Tagrisso submission for 1st-line nsclc

December 18, 2017

EMA accepts Tagrisso submission for 1st-line nsclc

November 28, 2017

AZ submits Tagrisso in Japan for 1st-line nsclc

November 27, 2017

AZ Fasenra receives FDA approval for severe asthma

November 15, 2017

Benralizumab positive CHMP in eosinophilic asthma

November 10, 2017

AZN: Year-To-Date and Q3 2017 Results Announcement

November 9, 2017

AstraZeneca and Aspen complete anaesthetics deal

November 1, 2017

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 249 decks. Every deck is listed under its year.